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Idiosyncratic drug reactions are a subset of adverse reactions frequently targeting the
liver, which become obvious only in large sample populations. Drug-induced
hepatotoxicity, occurring in a very small fraction of patients, poses a major challenge to
pharmaceutical companies due to its unknown mechanism(s) of action and deficient
models for study. In vitro model systems may have the potential to predict this liver
injury by generating conditions possibly representing key processes involved, both
directly and indirectly, in drug effects on cellular physiology. Our ultimate goal is to
develop an in vitro model effectively mimicking certain relevant aspects of the in vivo
response of the human liver. In our initial effort described herein, we have designed a
novel cell-based system using alternatively in both a human hepatoma cell line and
primary rat hepatocytes to study toxic effects in a background reflecting in vivo
inflammatory conditions. This background incorporates bacterial lipopolysaccharide
(LPS) administration along with inflammatory cytokines (tumor necrosis factor,
interferon y, interleukin-1 a, interleukin-113, and interleukin-6) previously shown to
increase in LPS-administrated rats.
Our study began with an investigation of toxicities that are induced by combinations
of five cytokines and LPS in HepG2 and C3A human hepatoma cell lines and in primary
rat hepatocytes. Informed by the results of these experiments, we selected representative
cytokine/LPS treatments and cell systems to examine drug-cytokine synergies in vitro
and were able to identify multiple idiosyncratic hepatotoxins that induced synergistic
toxicity in either the HepG2 cell line or primary rat hepatocytes. Finally, we measured the
sensitization of these cell systems to a panel of these drugs, given an inflammatory
background induced by an abbreviated set of cytokine treatments including four
cytokines and LPS. Analysis of this multivariate drug-cytokine toxicity data set yielded a
subset of representative cytokine treatments for future drug-cytokine synergy
investigations. This subset will be used to characterize the differences between cell
systems, including cultured human hepatocytes, and to hopefully develop a data-driven
partial least squares regression model that predicts idiosyncratic liver injury. The
implications are two-fold. First, this model could provide direction to pharmaceutical
companies in focusing their drug discovery and development. Second, it could help
physicians design better treatment plans for their patients.
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1 Introduction
Idiosyncratic drug reactions are a subset of adverse reactions that occur in a small
fraction of patients; their development is hypothesized to be due to the genetic
predisposition and environmental factors of an individual. Susceptibility to drug toxicity
is difficult to predict in preclinical studies and clinical trials because of the limited sample
sizes. Only when drugs hit the market do idiosyncratic reactions become obvious,
frequently targeting the liver [Waring et al., 2006]. Drug-induced liver disease is often
serious, requiring liver transplantation, and is sometimes fatal; it accounts for about half
of all cases of acute liver failure in the United States. In addition, hepatotoxicity (defined
as cytotoxicity of the hepatocyte, the key functional cell of the liver) is both the leading
cause of drug development failure during clinical trials and the leading cause of post-
marketing warnings and withdrawals. It poses a major challenge because of its unknown
mechanism and deficient models for study [Kaplowitz, 2005].
Preclinical animal toxicology studies usually fail to identify the risk of hepatotoxicity
during clinical trials or post-marketing; a survey examining the ability of animal studies
to predict human toxicities indicated that human hepatotoxicities had among the poorest
correlations with regulatory animal toxicity tests [Xu et al., 2004]. Cell-based assay
systems during the discovery phase of preclinical drug development are now being used
to probe the question of organ toxicity. According to Xu et al. [2004], in vitro systems
should be used in parallel to explore the diverse mechanisms of liver injury. The
predictive power of these systems should be greater for assays that assess early events in
pathogenic sequences. Ideally, both the endpoints of such an assay and the drug
concentrations necessary to elicit those endpoints would mimic human clinical
observations.
In culture, primary hepatocytes (either isolated from rodents or donated from human
liver samples) have limited retention of many of the key differentiated functionalities
necessary to properly study the metabolism and hepatotoxicity of a variety of drug
compounds [Brandon et al., 2003]. Moreover, human and rat hepatocytes express a
different repertoire of cytochrome p450 and Phase II metabolic enzymes, making cross-
species comparisons difficult. HepG2 cells and their subclone, C3A cells, are two
commonly used human hepatoma cell lines1 . These human hepatoma cell lines and other
human hepatocellular carcinoma cell lines, such as HepaRG and Huh-7, have even more
significant loss of expression of the key hepatocyte-enriched metabolic enzymes and are
thus often poor predictors of drug-related hepatotoxicity [Hewitt et al., 2007]. However,
even considering their deficiencies related to expression of hepatic enzymes and
transporters, primary cell systems and human hepatoma cell lines still offer the key
advantages of being scale-able to high-throughput approaches and tractable cell models
of liver function for systems-level investigations.
Recent rodent models developed by Roth and colleagues suggest that one of the
environmental factors that may determine an individual's susceptibility to idiosyncratic
drug hepatotoxicity is underlying inflammation during drug administration. Such animal
models employ administration of bacterial lipopolysaccharide (LPS) to mimic endotoxin
exposure and induce inflammatory cytokine release both systemically and within the liver
by resident liver macrophages (Kupffer cells). Roth and colleagues have shown that LPS-
I HepG2 and C3A cell lines are both of human hepatoma origin (although they are often incorrectly
identified as of human hepatocellular carcinoma origin) and are curated by ATCC (www.atcc.org).
induced inflammation enhances liver sensitivity to classical (aflatoxin B 1) and
idiosyncratic (ranitidine, trovafloxacin) hepatotoxins at concentrations that alone have
minimal effects, but does not sensitize the liver to non-idiosyncratic drug compounds of
similar pharmacological functions [Barton et al., 2000; Luyendyk et al., 2006; Waring et
al., 2006]. What accuracy LPS-treated animal models will have in predicting human liver
toxicity over a broad spectrum of compounds is uncertain, in part because animal models
are inherently low-throughput and results from only a few sets of pharmacological
compounds have been published to date. Additionally, the specific roles of the multiple
molecular mediators of LPS-induced inflammation (extracellular cytokines and
intracellular signaling molecules) in regulating the sensitizations to drug-induced liver
toxicity have not be identified in these animal models, but have been preliminarily
examined in Kupffer cell-hepatocyte coculture models [Tukov et al., 2006].
Motivated by these efforts, we are working to develop an in vitro model to mimic the
in vivo response of the liver to drugs upon LPS-related inflammation. In work described
herein, we have designed a novel cell-based system utilizing both a human hepatoma cell
line and primary rat hepatocytes to study the toxic effects of multiple idiosyncratic
hepatotoxins in the presence of defined inflammatory cytokine environments. To mimic
the in vivo inflammatory response to LPS administration, our cell systems were treated
with multiple combinations of LPS and the inflammatory cytokines tumor necrosis factor
(TNF), interferon-y (IFNy), interleukin-la (IL-la), interleukin- 10 (IL-10), and
interleukin-6 (IL-6), which are shown to be upregulated within the liver in LPS-
administered rats [Bergheim et al., 2006]. Our in vitro model does not explicitly include
the non-parenchymal cells, such as Kupffer cells, that mediate the liver's response to
LPS, but instead the role of these cells is reproduced through the addition of the
previously mentioned inflammatory cytokines in cell culture experiments containing
hepatocytes or hepatoma cells only.
Our study began with an investigation of cytotoxicities that are induced by
combinations of these five cytokines and LPS2 in two human hepatoma cell lines (HepG2
and C3A) and primary rat hepatocytes to select representative cytokine/LPS treatment
conditions and cell systems for examination of drug-cytokine interactions in vitro.
Informed by the results of these experiments, we set forth to identify whether synergies
exist between the selected representative cytokine cocktail and multiple pharmacologic
compounds classified as idiosyncratic hepatotoxins in inducing toxicity in either a human
hepatoma cell line or primary rat hepatocytes. After identifying multiple idiosyncratic
hepatotoxic drugs that exhibit synergy with a representative cytokine cocktail, we asked
how this selected set of drugs sensitized both cell systems to a spectrum of cytokine
treatment conditions (containing four cytokines and LPS). This multivariate drug-
cytokine toxicity data set was then analyzed to identify a subset of cytokine combinations
for future drug-cytokine synergy investigations in cultured human hepatocytes. It was
also used to characterize the differences between cell systems that differ in species
(primary rat versus primary human hepatocytes) and in transformation state (human
hepatoma cells versus primary human hepatocytes) in this drug-cytokine co-treatment in
vitro model. In future efforts, we hope to develop a data-driven partial least squares
regression (PLSR) model, based on the canonical cue-signal-response methodology, to
2 In this text, experiments with combinations of four cytokines and LPS will be referred to as "5-
cytokine/LPS" experiments and those with combinations of five cytokines and LPS will be referred to as
"6-cytokine/LPS" experiments.
predict idiosyncratic liver injury based on knowledge of how drug therapies affect
hepatocyte signaling networks in the way of Miller-Jensen et al. [2007].
The implications of this work and future modeling efforts are twofold. First, this in
vitro cellular model of inflammatory cytokine-mediated hepatotoxicity could identify
potential hepatotoxins earlier in the drug development processes. Or, similarly, a
predictive PLSR model could provide direction to pharmaceutical companies in focusing
their drug discovery efforts away from compounds that would significantly affect cellular
mediators of drug-cytokine toxicity synergies. Second, our work could help physicians
design better treatment plans for their patients by stratifying patients into different drug
treatment programs depending on their preexisting inflammatory conditions and based on
knowledge of particular synergies that exist between candidate drugs and various
inflammatory cytokine environments.
2 Materials and methods
2.1 Cell culture
2.1.1 Human hepatoma cell lines
On Day 1 of the 6-cytokine/LPS multiplex experiment, 100 ýtL of HepG2 and C3A
cells from human hepatoma cell lines were grown on 96-well, collagen I-coated, black
plates with clear bottoms (BD) in lot-controlled USDA tested 10% fetal bovine serum
(HyClone)-containing EMEM (ATCC) supplemented with 1% penicillin-streptomycin
(Invitrogen) at 30,000 cells/well, such that they were confluent the next day. At this time
the media was aspirated, and cells were treated with various cytokine/LPS combinations
in the previously described media. LDH release and intracellular ATP were measured 24
and 48 hours following dosing.
The HepG2 plating protocol remained the same during subsequent experiments
(Figure 1). However, on Day 2 the media used during seeding was aspirated, and 5
[tg/mL insulin (R&D Systems) was added to the cells in 100 [tL of serum-free media
supplemented with antibiotics. On Day 3, cells were co-treated with various
cytokine/LPS combinations and, in most cases, idiosyncratic and non-idiosyncratic drugs;
these dosing solutions were administered in the same serum-free, insulin-containing
media supplemented with antibiotics. Cells were dosed with cytokine/LPS combinations
and drugs simultaneously so that drug exposure occurred at maximum cytokine/LPS
stimulation. Hepatotoxicity was then assayed between 12 and 48 hours using in vitro
toxicity assays.
Cells were regularly passaged on a biweekly basis. HepG2 and C3A cells between
passages 45 and 60 were used in 6-cytokine/LPS multiplex experiments. HepG2 cells
from passage 12 were used in the experiment identifying drug-cytokine synergies, and
cells from passage 14 were used in the 5-cytokine/LPS multiplex experiment.
Cell treatment protocol
Primary rat Day 1 Day 2 Day 3 Day 4-5
hepatocytes Seed cells - Add Matrigel ' Treat cells Assay cellsoverlay
HepG2 Day 1 Day 2 Day 3 Day 4-5
cell line Seed cells Starve cells Treat cells Assay cells
Figure 1. The timeline of experiments to identify drug-cytokine synergies and
synergies across a 5-cytokine/LPS inflammatory landscape included growing
primary rat hepatocytes in a collagen I-Matrigel sandwich configuration and serum-
starving HepG2 cells.
2.1.2 Primary rat hepatocytes
Primary rat hepatocytes were isolated as described in Sivaraman et al. [2005].
Primary hepatocytes were isolated from male Fisher rats using a two-step collagenase
procedure including multiple 50g centrifugations and a Percoll (Sigma) clarification
centrifugation to increase hepatocyte purity and reduce contamination with non-
parenchymal cells. Cell viability and yield were routinely greater than 90% and 300
million cells, respectively, as assessed by trypan blue exclusion staining using a Vi-CELL
instrument (Beckman-Coulter). Purity of hepatocytes and non-parenchymal cells
following Percoll isolation was assessed using a flow cytometry-based assay utilizing
various liver cell type antigens as described in Cosgrove et al. [in prep]. Median cell type
fraction values were as follows: 97% hepatocytes (cytokeratin-18 + cells), 0.4% Kupffer
cells (ED2+ cells), 0.4% stellate cells (GFAP+ cells), and 0.2% sinusoidal endothelial
cells (SE-1 + cells).
Primary rat hepatocytes were plated and cultured in hepatocyte growth medium
(HGM) based on that described in Block et al. [1996]. HGM is a phenol red-free DMEM
(Gibco)-based medium that contains necessary amino acids, sugars, trace metals,
hormones, and 5 pg/mL insulin (Sigma), but does not contain serum. In this work, the
Block et al. HGM formulation was modified to contain 300 ng/mL trichostatin A (Sigma)
and was made without EGF. See Appendix 1 for the full HGM formulation. Following
Percoll isolation, primary rat hepatocytes were plated in 100 [tL/well HGM at 100,000
cells/cm2 (32,000 cells/well) in 96-well, collagen I-coated plates (BD) (Figure 1). Four
hours after plating, culture media was replaced with fresh HGM. On Day 2 of culture, an
overlay of the reconstituted basement membrane solution Matrigel (BD) was added on
top of the hepatocytes to mimic the complex extracellular environment and to maximize
cellular differentiation. Ice-cold Matrigel (phenol red-free, growth factor-reduced) was
added to ice-cold HGM to a final concentration of 0.25 mg/mL and was added at 100
tL/well to freshly aspirated culture wells. Matrigel was allowed 24 hours to form a gel
overlay before the media was aspirated on Day 3 and fresh HGM was added containing
drugs and/or cytokines according to the treatment and assay protocols outlined for the
HepG2 cells. For the preliminary 6-cytokine/LPS multiplex experiments, the Matrigel
overlay step was omitted, and the hepatocytes were treated with cytokines in 100 tL/well
fresh HGM on Day 2 of culture.
2.1.3 Cytokines, LPS, and drugs
The 6-cytokine/LPS multiplex data set was collected using cytokines at the lowest
concentrations listed in Table 1. In experiments in which cells were co-treated with both
drugs and cytokines, dosing solutions were prepared to standardize administration using
cytokines at the highest concentrations listed in Table 1. Recombinant human and rat
cytokines were obtained from R&D Biosystems and LPS serotype S from E. coli
0111 :B4 was obtained from Sigma. Stock solutions of idiosyncratic and non-
idiosyncratic drug pairs (Table 2) from the same pharmacologic class (Table 3) were
prepared at 200x in 100% DMSO (Sigma) and diluted in insulin- and cytokine-
containing HepG2 or primary rat hepatocyte media to lx concentrations at 0.5% DMSO.
As described in Section 4, a representative cytokine cocktail denoted "cytokine mix C"
was used in a subset of the drug-cytokine co-treatment experiments; it contained 10
jtg/mL LPS, 100 ng/mL TNF, 100 ng/mL IFNy, and 20 ng/mL IL-la.
Table 1. Concentrations of cytokines and LPS used in this study.
Cytokine Concentration (ng/mL)
LPS S1 10,000
TNF-a 100
IFN-y 20-100
IL-la 10-20
IL-1f3 10-20
IL-6 2.5-20
Table 2. Drugs ordered from the following manufacturers or procured from
collaborators at Pfizer.
Drug Manufacturer
Aspirin Sigma
Buspirone hydrochloride Sigma
Cimetidine Sigma
Clarithromycin Sequoia Research
Entacapone Sequoia Research
Famotidine Sigma
Levofloxacin Fluka BioChimika
Nefazodone hydrochloride Sigma
Nimesulide Sigma
Ranitidine hydrochloride Sigma
Telithromycin Sequoia Research
Tolcapone Pfizer
Trovafloxacin Pfizer
Table 3. Idiosyncratic and non-idiosyncratic drugs used in this study. The
pharmacologic class of each is listed, along with its maximum concentration encountered
by the liver. Those compounds in red have been identified as causing drug-induced liver
injury (DILI) by our collaborators at Pfizer. Results from Roth and colleagues are
summarized from Luyendyk et al. [2006] and Waring et al. [2006].
Compounds to investigate in drug-cytokine hepatotoxicity synergy model
100*Cmax human
plasma concentration
(high end of
Drug "therapeutic window")
Buspirone 0.5 pM
Nefazodone 86 IpM
Clarithromycin 334 pM
Telithromycin 277 IpM
Aspirin 552 ipM
Nimesulide 2108 ipM
Famotidine 30 piM
Ranitidine 142 ipM
Cimetidine 1542 pM
Levofloxacin 1577 pM
Trovafloxacin 769 pM
Entacapone 393 pM
Tolcapone 2084 pM
Color key:
Pharmacologic class
Synergy in
LPS-administered
animal model
(Roth group)
serotonin receptor inhibitor not reported
serotonin receptor inhibitor not reported
antibiotic not reported
antibiotic not reported
non-steroidal anti-inflammatory drug not reported
non-steroidal anti-inflammatory drug not reported
histamine H2-receptor antagonist
histamine H2-receptor antagonist +
histamine H2-receptor antagonist not reported
antibiotic
antibiotic +
catechol-O-methyl transferase inhibitor not reported
catechol-O-methyl transferase inhibitor not reported
Compound not associated with liver injury
Compound associated with idiosyncratic liver injury (DILI P2)
2.2 Assays
2.2.1 Rationale
We chose to multiplex several of Promega's cell viability, cytotoxicity, and apoptosis
assays to measure the endpoints during this screen of multiple drugs across inflammatory
cytokine backgrounds. We could have instead used various imaging techniques or a
variety of sub-lethal toxicity endpoint assays, but we found that the high-throughput
nature of these lethal toxicity assays and their ease of use outweighed the benefits of the
former. These assays may be less informative than a flow cytometry-based apoptosis
assay, for example, but they allowed us to collect a depth and breadth of data that would
not have otherwise been possible and that discriminated between the many possible
cytokine combinations.
2.2.2 LDH release assay
The CytoTox-ONETM Homogenous Membrane Integrity Assay (Promega) was used
to measure cytotoxicity by the release of lactate dehydrogenase (LDH), a stable cytosolic
enzyme, into the surrounding medium upon cell lysis (Figure 2). It is a fluorometric
method used to estimate apoptotic and necrotic cell death by loss of membrane integrity
in a mixed population of viable and damaged cells. LDH released into culture
supernatants is measured with a 10-minute coupled enzymatic assay driven by the
presence of excess lactate and NAD+ . LDH catalyzes the conversion of these substrates
into pyruvate and NADH; the latter subsequently drives the diaphorase-catalyzed
reduction of resazurin to produce fluorescent resofurin. Fluorescence is proportional to
the number of lysed cells. In some cases, cell lysis reagent was added to positive control
wells prior to the addition of CytoTox-ONETM Reagent to generate a maximum LDH
release control. Also, stop solution was not added.
Lactate Pyruvate
NAD+ NADH
SReri Resorutin sazurin
Figure 2. LDH substrate of coupled reduction-oxidation reactions resulting in the
production of fluorescent resofurin. LDH is released by cells suffering a loss of
membrane integrity. Supplying the excess substrates lactate, NAD+, and resazurin,
ensures fluorescence is proportional to the number of necrotic cells [Promega].
2.2.3 Effector caspase activity assay
The Caspase-Glo® 3/7 Assay (Promega) is a luminescent method used to measure
apoptosis in adherent cells. After causing cell lysis, it provides the luminogenic substrate
DEVD-aminoluciferin for caspase-3/7 cleavage and luciferase to generate a luminescent
signal by consuming the liberated free aminoluciferin (Figure 3). The resulting
luminescence is proportional to caspase-3/7 activity. Samples were incubated for one
hour.
H
Z-DEVD-N S N COO H
Caspase-3/7 N S
HN S / COOHH, S\+ 
ATP + 02Z-DEVD- + N S
UItraGIo Tm Luciferase
Mg2 ÷
Figure 3. Luminescent signal generated following caspase-3/7 cleavage of DEVD-
aminoluciferin. Cleavage of the luminogenic caspase-3/7 substrate releases free
aminoluciferin into the surrounding medium for luciferase action [Promega].
2.2.4 Intracellular ATP assay
The CellTiter-Glo Luminescent Cell Viability Assay (Promega) is a method of
measuring cell viability via its correlation with intracellular ATP. The Cell-Titer-Glo®
Reagent causes cell lysis and the release of ATP into the surrounding culture medium;
upon loss of membrane integrity, the cell loses its ability to synthesize additional ATP.
The reagent simultaneously inhibits endogenous ATPases and provides the reactants for a
luminescent reaction to measure ATP.
2.2.5 Calculating results
The average value of culture medium background fluorescence or luminescence was
subtracted from all experimental wells. Experimental values were then normalized to the
average signal from untreated control wells (containing no cytokines and 0.5% DMSO
when appropriate). Assay data is therefore presented in Relative Fluorescence (RFU) or
Luminescence Units (RLU).
2.2.6 Multiplexing homogenous assays
These assays were used in parallel such that more than one data set was collected
from the same sample. In cases in which the intracellular ATP assay was multiplexed
with the LDH release assay, all media was transferred to a separate assay plate for the
LDH release assay and 100 [tL of fresh media was added to each well on the original
assay plate. The ATP release assay protocol was then followed as recommended by the
manufacturer. Alternatively, 50 ptL of culture supernatant was removed to a separate
white assay plate (Nunc) to gather cytotoxicity data using the LDH release assay, leaving
the original assay plate available for caspase activity measurements of apoptosis.
When multiplexing assays it is especially important to understand what a given assay
is measuring and how it is correlated with cell viability, cytotoxicity, or apoptosis. It is
also important to understand the kinetics of the cell death process to inform decisions like
the choice of assay endpoint. For example, cells undergoing rapid necrosis, characterized
by loss of membrane integrity and metabolic shutdown, do not express apoptotic markers.
On the other hand, apoptotic cells transiently express those markers before undergoing
secondary necrosis in vitro.
2.3 Analytical techniques
2.3.1 Factorial analysis
In this study we first performed a battery of experiments to measure the effects of,
and identify the synergies between, five cytokines and LPS on hepatocellular viability,
cytotoxicity, and apoptosis. Later, we set forth to detect synergies between five
inflammatory agents and a variety of idiosyncratic and non-idiosyncratic drug
compounds. In both cases, we used a full pq factorial design, where q is the number of
variables (factors) and p is the number of levels at which the variable is tested; there were
26 = 64 combinations in the first case and 25 = 32 in the second. The concentrations at
which these cytokines were tested are explained in Section 2.1.3. This analytical
technique identifies main effects and interactions and informs further experimentation. In
this case, it measured the additive or subtractive effect of any single or group of
conditions on toxicity. The following explanation was adapted from Box et al. [1978].
The main effect of a variable is its average effect on the response, regardless of the
levels of the other variables. In our two-level factorial design for six inflammatory
agents, the main effect of variable i is given by
main effect = y,..... - Y ......
where y ..... is the average measured outcome in the presence of a given cytokine and y ......
is the average value in its absence. Each of the calculated main effects is therefore
dependent on all 64 of the responses. Also, each is determined with the precision of 32
replicated experiments.
In addition to more precisely measuring the additive effects of variables on outcomes
compared to an experimental method in which one variable is varied at a time, this
analytical technique has the added benefit of calculating potentially synergistic
interactions that may result from the presence of multiple variables in a system using
fewer observations than the one-factor-at-a-time method. For variables i and j in our 26
factorial design, the i x j interaction is
ix jinteraction....
2
or half the difference between the average effect of variable i in the presence and
absence of j. By extension, for variables i through m, the six-factor interaction is
Y6/6 - Y5/6 + Y4/6 - Y3/6 + Y2/6 - Y1/ 6 + YO/6ixjxkxlxmxn= 32
where, for example, y 3/ 6 represents all the outcomes in the presence of only three of the
six inflammatory agents. It is important to remember that each interaction can be defined
as half the difference between two averages, and that the outcome in the presence of all
variables, yijkmn,, has a positive effect on any main effect or interaction.
Before the main effects and interactions can be interpreted, the associated standard
errors must be calculated. With replicated observations, the pooled estimate of run
variance is
g"(n -I)s2
S2 i=
(ni1 -1)
i= 1
where g is the number of conditions; and ni is the number of replicates, ni -1 is the
degrees of freedom, and si2 is an estimate of the variance 2', for the ith condition. Each
effect or interaction is the difference between two averages, y, - y_, so the variance v of
each effect or interaction is
V= + 0- 7-(n+, n
where n+ is the total number of replicates used to calculate y+ and n_ is the total number
of replicates used to calculate y_. The estimated standard error of each main effect or
interaction is calculated by
standard error = +±
Factorial analysis calculations were performed on fold change versus no cytokine
control data in all cases. The guidelines governing the interpretation of factorial effects
tell us that main effects cannot be interpreted individually if either plays a role in
significant higher-order interactions.
Statistical significance of each factorial effect or interaction y, was evaluated using
a one-sample, two-tailed t-test. A 95% confidence interval for each effect or interaction
was calculated using its standard error v and an appropriate critical t-value t*, which was
calculated as a function of the number of biological replicates n and the desired
statistical confidence level a.
CIS5% = Yij tnl,a . V
A Bonferroni correction to the statistical confidence level was used to account for
multiple comparisons because the significance of multiple effects and interactions were
evaluated simultaneously. For example, in the evaluation of the 5-cytokine/LPS/drug co-
treatment experiments, five biological replicates were used and 31 different effects or
interactions were evaluated. Thus, a statistical confidence level of a = 0.05/31 = 0.0016
was used, yielding a critical t-value of t4 .00o1 6 = 7.56. If the 95% confidence interval of a
given effect or interaction did not contain zero (the null hypothesis of no effect), then the
effect or interaction was deemed statistically significant.
2.3.2 Principal component analysis
A principal component analysis (PCA)-based data mapping approach was used to
examine co-variations in the 6-cytokine/LPS combinatorial toxicity data set collected in
the three hepatocyte cell systems. A data matrix was constructed containing rows
representing the 64 unique cytokine treatment combinations and 12 columns representing
both discretized classifications of the six cytokine treatment variables and the measured
LDH release values for HepG2 cells, C3A cells, and primary rat hepatocytes at 24 and 48
hours post-treatment. The cytokine treatment columns were formulated as discretized
treatment concentrations with '0' representing no cytokine and '1' representing a
cytokine that was included in a given treatment. The LDH release data columns were
formulated as fold change values separately normalized for each cell type and time point
(as plotted in Figures 4 and 6). Thus, the values in each row of the data matrix could
project as a series of coordinates in a multi-dimensional cytokine treatment classification-
and toxicity data-space [Janes et al., 2006]. A PCA algorithm was implemented (SIMCA-
P, U-Metrics) to map the multi-dimensional cytokine treatment-/toxicity outcome-space
onto a set of principal component axes to capture a significant amount of the co-variation
in the data matrix. Preceding PCA mapping, each column of the data matrix was
separately mean-centered and variance-scaled following accepted data pre-processing
methods for disparate data types [Geladi et al., 1986]. A two-component PCA map was
obtained that captured 43% of the entire variation in the data set (as measured by
cumulative R2) with the first and second principal component containing 30% and 13%
of the variation, respectively. Additional principal components provided non-significant
additions in capturing variation in the data matrix (R2) and/or cross-validated predictions
based on the principal component mapping (Q2) (data not shown). PCA loadings for each
column of the data matrix are plotted in Figure 7 and represent how data from each
cytokine treatment classifier or LDH outcome measurement map onto the two principal
component axes. Similar patterns of loadings onto these two principal component axes
for sets of treatment classifiers or cell systems indicate related co-variation across the
entire set of 64 unique cytokine treatments.
2.3.3 Mutual information
In the 6-cytokine/LPS experiments, cytokine treatment variables whose presence or
absence were most informative of the six measured LDH release outcomes (HepG2, C3A
or primary rat hepatocyte cells at 24 or 48 hours) were computed [King and Tidor, in
prep]. Cytokine treatment variables were scored for information content by estimating the
mutual information between the cytokine variable and the set of outputs, using a second
order joint entropy approximation.
To identify characteristic subsets of the 32 cytokine conditions in the 5-
cytokine/LPS/drug experiments, 1000 subsets ranging in number of included unique
cytokine treatments from 4 to 32 were chosen at random for all possible permutations.
These subsets were scored by estimating the joint entropy of all drug and DMSO control
treatment responses. Caspase 3/7 activity data in the HepG2 cells at 24 hours post-
treatment was used as a test data set for this approach. The subset of each size with the
highest computed joint entropy was chosen as the most representative.
2.3.4 Euclidean clustering
Hierarchical clustering was conducted to identify and distinguish clusters of toxicity
outcomes based on cytokine treatment conditions, cell system, and/or drug co-treatments.
For the 6-cytokine/LPS combinatorial experiments, LDH release data from HepG2 cells,
C3A cells, and primary rat hepatocytes at 24 and 48 hours post-treatment was normalized
to fold change (separately for each cell system and time point) and subjected to
hierarchical clustering. Hierarchical clustering was performed in Matlab (Mathworks)
using a Euclidean distance metric with linkages evaluated by the unweighted pair-group
method with arithmetic averages [D'haeseleer, 2005]. Clustering was separately
conducted on the 64 unique cytokine treatments and the six cell systems/time points. For
the 5-cytokine/LPS combinatorial experiments in the presence of drug co-treatments,
clustering was performed as described above for a representative data set (caspase 3/7
activity at 24 hours post-treatment in HepG2 cells) and was used to distinguish clusters of
both cytokine treatment conditions and drug co-treatments.
2.3.5 Drug-cytokine synergy calculations
Synergistic interactions between drugs and inflammatory agents are those effects that
are greater than the sum of their individual effects. Therefore the cytotoxic effect of
cytokine mix C alone as measured by LDH release was added to each toxicity value of
drug alone across the range of tested concentrations at three time points in both HepG2s
and primary rat hepatocytes. These projected dose-response curves describe the toxicity
that would be predicted for each drug if there was a purely additive cytotoxic effect
between the compound and cytokine mix C. Drugs that synergized with the inflammatory
cytokine background were easily identifiable using this intuitive technique since their
measured toxicity values exceeded those predicted by simple addition. For all
combinations of drug, cell systems, and time points, the drug concentration that exhibited
the greatest synergistic toxicity above the predictive additive toxicity was identified and
reported in Table 4.
3 6-cytokine/LPS multiplexing
3.1 Results from human hepatoma cell lines
A number of general trends become obvious upon inspecting the data set collected
from the human hepatoma cell lines (Figures 4, 5). Unfortunately, however, the limited
number of replicates in this cell line experiment makes the statistical significance of the
data subject to skepticism.
Very little cytotoxicity was measured by the LDH release assay across the spectrum
of cytokine backgrounds in HepG2s at 24 hours, an observation reiterated by the
negligible factorial effects calculated for the time point (Figure 4). In the presence of a
single cytokine, only minimal cell death was seen in either cell line at both time points; in
contrast, the most LDH release was measured in the presence of some of the highest-
order cytokine combinations. The C3A cell line exhibited a similarly modest level of cell
death as measured by the LDH release assay at 24 hours, with a few notable exceptions in
the presence of three- or higher-order cytokine combinations. The common inclusion of
LPS in these apparently cytotoxic cytokine combinations explains the strong positive
factorial effect of the bacterial endotoxin. LPS treatment co-varied with the LDH release
data from the C3A cells at 24 hours in the PCA map (Figure 7). More cytotoxicity was
evident at 48 hours in both cell lines; by inspection it seems that IL-la was a common
denominator among the most cytotoxic cytokine combinations in HepG2s, just as the
presence of TNF and IFNy seem to affect cell death in C3As (Figure 4).
Cell viability data from the intracellular ATP assay was very noisy and did not
correlate with increased LDH release (Figure 5). No clear trends were evident and the
fold change assay values only varied across a twofold range; this variability was
propagated into the factorial analysis. The unreliable data may result from the effects of
metabolic variation induced by cytokine treatment.
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Figure 4. LDH release data set from the 6-cytokine/LPS multiplex experiment in
both human hepatoma cell lines at two time points. Cytokine mix C is identified in the
treatment matrix, and mean assay values are presented as fold change versus the no
cytokine control.
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Figure 5. Intracellular ATP data set from the 6-cytokine/LPS multiplex experiment
in both human hepatoma cell lines at two time points. Cytokine mix C is identified in
the treatment matrix, and mean assay values are presented as fold change above the no
cytokine control.
3.2 Results from primary rat hepatocytes
Primary rat hepatocytes underwent only background levels of apoptosis at 24 hours
according to the caspase activity assay, and the LDH release assay revealed moderate
cytotoxicity with higher-order cytokine combinations, a trend heightened at 48 hours
(Figure 6). At 24 hours, the factorial effects as determined by both caspase 3/7 activity
and LDH release assays revealed minimal meaningful main effects or multi-factor
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interactions. In fact, none of the factorial effects calculated from this primary rat
hepatocyte data set are statistically significant (Figures Al, A2). Qualitatively, however,
it would seem that hepatocyte apoptosis was highly correlated with the presence of either
TNF or IL-la at 48 hours, an observation supported by the strong positive factorial
effects of these two cytokines (Figure 6). It is interesting that the main effect of IFNy at
24 hours was amplified at 48 hours and that this cytokine also appeared in the notable
two-factor interaction with LPS at this later time point. Importantly, only the IFNy x LPS
interaction could be subject to interpretation (Section 2.3.1) if the results of this factorial
analysis were, in fact, statistically significant.
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Figure 6. Caspase 3/7 activity and LDH release data sets from the 6-cytokine/LPS
multiplex experiment in primary rat hepatocytes at two time points. Cytokine mix C
is identified in the treatment matrix, and mean assay values and factorial effects are
presented.
3.3 Trends across the data set
According to the PCA plot of the first two principal components, the LDH outcomes
strongly impact the model, as evidenced by their distance from the origin, while the
cytokines, especially IL-6 and IL-10, seem to have little effect on cytotoxicity (Figure 7).
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The 48 hour data from all three hepatocyte cell systems group together in the PCA plot as
outcomes with similar co-variations in LDH release. The five cytokines also appear to co-
vary more closely with each other than with LPS.
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Figure 7. PCA plot of LDH release data sets from both the human hepatoma cell
lines and primary rat hepatocytes. The first component explains 30% of the variation
and the second component 13%. The C3A data at 24 hours is strongly co-varied with the
LPS treatment in both principal components.
In addition, a Euclidean clustering of the same LDH release data set greatly
distinguished the cytokine-induced cytotoxicity in primary rat hepatocytes at 48 hours
from the other combinations of cell system and time point, as the primary rat hepatocytes
demonstrated a far greater cytotoxic response than the other cell systems at either time
point (Figure 8). Clustering also illustrated the similarity between LDH release outcomes
of HepG2s and C3As. LDH release generally increased in the presence of higher-order
cytokine combinations, as discussed earlier. In particular, we identified cytokine mix C
(TNF, IFNy, IL-la, and LPS) as the least cytotoxic cytokine combination among the
most cytotoxic combinations grouped together at the highest level of clustering. A mutual
information analysis of the same LDH release cytotoxicity data set revealed that LPS
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treatment was the most informative of the entire data set, followed by IFNy, IL- la, TNF,
IL-6, and IL-103 (Figure 9).
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Figure 8. Euclidean clustering of LDH release data sets from both the human
hepatoma cell lines and primary rat hepatocytes. Cell systems clustered by time point,
with the HepG2 cell line and its subclone clustering closely at both 24 and 48 hours. The
primary rat hepatocyte data set from 48 hours was by far the most cytotoxic. Cytokine
mix C is identified as the least cytotoxic cytokine combination among the combinations
that exhibited the most cytotoxicity and clustered together at the highest level.
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Figure 9. Mutual information evaluation to choose the most informative cytokines.
A second-order joint entropy approximation was used [Bracken King].
3.4 Conclusions
To maximize our efficiency in subsequent experiments, we chose to only continue
testing the hepatotoxic responses of HepG2s and primary rat hepatocytes. Keeping in
mind that our ultimate goal was to identify a cell system that closely mimics an in vivo
human liver, it seemed prudent to maintain the use of at least one of the human hepatoma
cell lines. Clustering illustrated the similarity between LDH release outcomes of HepG2s
and C3As, which would be expected since C3As are a HepG2 subclone (Figure 8). To
capture the greatest variability across the cell systems, we decided to keep using the
HepG2 cell line, which clustered farthest from the primary rat hepatocytes at each time
point.
Clustering of the 64 cytokine treatment combinations in order of increasing toxicity
across the outcomes was also informative (Figure 8). Cytokine mix C was chosen for use
1N1o1
in subsequent experiments due to its sub-maximal hepatotoxic effects; our aim was to
observe drug-cytokine synergies across a range of drug concentrations. The absence of
IL-6 and IL- 10 from this combination is reminiscent of their minimal effect on
cytotoxicity as highlighted in the PCA and mutual information results (Figures 8, 9). In
fact, mutual information quantitatively substantiated our decision to eliminate IL-10 from
future experiments (Figure 9). Our decision was further supported by the biology; both
IL-la and IL- 10 bind to the same receptor (IL-1R), eliciting similar cell signaling
responses in hepatocytes, though often with differing potency depending on other co-
stimulations [Luedde et al., 2006].
4 Identifying drug-cytokine synergies
4.1 Rationale
It was important to identify the concentration of each drug which best synergized
with a representative inflammatory cytokine background (cytokine mix C) to cause
cytotoxicity in both HepG2s and primary rat hepatocytes for use in the 5-cytokine/LPS
multiplex experiment. To achieve this goal, we compared the dose-response curves of
drug pairs at the same molar concentration, as opposed to at equivalent multiples of their
Cmax values (maximum plasma drug concentrations in human administration). Scaling
relative to the Cmax values was avoided because these could differ drastically for any
given pair of drugs, due to differences in compound efficacy and pharmacodistribution
(Table 3). Also, testing each drug pair at the same molar concentration provides more
comparable data in an in vitro system and is more applicable in a model trained to
identify idiosyncratic hepatotoxicity during laboratory development, prior to clinical
testing. As reported in Table 3, 100*Cmax values provide an estimate of the worst-case
liver exposure and exist at the high end of the "therapeutic window," or the dose range
that elicits therapeutic effects without causing toxicity alone. Preliminary experiments
were used to inform the concentration range that was tested in both cell systems using
LDH release and caspase activity assays at three time points.
4.2 Comparison of drug pairs across an inflammatory background
Cytotoxicity and apoptosis were measured spanning a range of drug concentrations at
three time points in both cell systems. Only LDH release measurements were considered
in identifying the optimal drug concentration for each analogous pair since the LDH
release assay captures both apoptotic and non-apoptotic cell death.
Nefazodone, the idiosyncratic drug of the serotonin receptor inhibitor drug pair,
showed clear drug-cytokine synergy at about 75 [iM in both cell systems at 24 hours
(Figure 10). This synergy was also evident at 48 hours in the primary rat hepatocytes. In
HepG2s, the earlier onset of synergistic cytotoxicity may explain the decrease in
measured LDH release at 48 hours; released LDH has a half-life of approximately 9
hours in the surrounding medium. The non-idiosyncratic analog buspirone exhibited
minimal toxicity, regardless of an inflammatory cytokine background (Figure 10).
In the clarithromycin-telithromycin drug pair, it was interesting that clarithromycin
displayed cytokine synergies at about 175 gM (Figure 11). Although clarithromycin was
included in this study as telithromycin's non-idiosyncratic analog, it is also associated
with idiosyncratic liver injury, although to a lesser extent. It caused synergistic
hepatotoxicity at 24 and 48 hours in both cells systems. On the other hand, telithromycin
did not appear to cause this same toxicity, and instead somewhat irregular dose-response
curves were measured at both later time points (Figure 11). A hypothesis for this
potentially unreliable data is discussed in Section 6.
Although both aspirin and nimesulide never demonstrated clear drug-cytokine
synergy in the primary rat hepatocytes (nimesulide-mediated effects seem to dominate),
nimesulide did induce synergistic toxicity at about 450 [LM in the human hepatoma cell
line at 24 hours (and to a lesser extent at 12 hours as well) (Figure 12). These effects had
faded by 48 hours, similar to nefazodone. No aspirin-cytokine synergy was observed in
HepG2 cells.
In contrast, ranitidine-cytokine synergy was measured by LDH release at 48 hours in
primary rat hepatocytes (and to a lesser extent at 24 hours), but not in the cell line (Figure
13). This comes with the caveat that this synergy was observed at about 450 [tM
(317*Cnx.), a far higher concentration than is probably physiologically relevant. Also,
similar to the clarithromycin-telithromycin drug pair, it was the non-idiosyncratic analog
that displayed drug-cytokine synergy. However, ranitidine is also associated with liver
injury, although to a lesser extent than cimetidine, and tested positive for hepatotoxicity
in Roth's rat model (Table 3). Famotidine, the histamine H2-receptor antagonist analog
used by Roth, will probably be used as the non-idiosyncratic analog to ranitidine in future
experiments with this class of compounds.
Trovafloxacin is another compound considered to be an idiosyncratic hepatotoxin
according to the Roth model. It too showed clear drug-cytokine synergy at about 450 [IM
in both cell systems at all time points, most notably at 24 hours (Figure 14). In addition, it
caused a much higher level of measured cytotoxicity in the HepG2 cell line compared to
primary rat hepatocytes than was seen for any of the other drugs. To compare, its non-
idiosyncratic analog levofloxacin exhibited negligible synergy across the board, as
measured by LDH release (Figure 14).
The pair of catechol-O-methyl transferase inhibitors, entacapone and tolcapone,
which proved fickle during preliminary experiments, once again did not show clear drug-
cytokine synergy (Figure 15). These drugs were tested at high molar concentrations due
to their relatively high 100*C. values, possibly explaining their poor solubility. Also,
like telithromycin, these drugs produced potentially-unreliable dose-response curves that
may have been caused by unknown off-target effects.
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Figure 11. Dose-response curves of the clarithromycin-telithromycin drug pair from
the mean LDH release data in both cell systems at three time points. Clarithromycin
showed clear drug-cytokine synergy around 175 tM at 24 and 48 hours in HepG2s and
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Figure 14. Dose-response curves of the levofloxacin-trovafloxacin drug pair from
the mean LDH release data in both cell systems at three time points. Trovafloxacin
showed clear drug-cytokine synergy around 450 RM at 24 and 48 hours in HepG2s and
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4.3 Drug-cytokine synergy calculations
As explained in Section 2.3.5, we then set about to qualitatively identify a single drug
concentration that demonstrated synergistic toxicity in both cell systems for each
compound. A representative graph is shown below (Figure 16), with the concentration
listed from the experiment in which the projected toxicity value most under-predicted that
obtained experimentally. These results are compiled in Table 4. Table 5 presents the
drugs and their corresponding concentrations that were selected for the 5-cytokine/LPS
multiplex experiments.
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Figure 16. Measured dose-response curves for the buspirone-nefazodone drug pair
compared to those predicted by the additive cytotoxicities of drug and an
inflammatory cytokine background. Data is presented from the mean LDH release data
set in both cell systems at 24 hours. Error bars represent the standard error across four or
more biological replicates.
Table 4. Calculated drug concentrations displaying the maximum drug-cytokine
synergy in both cell systems at three time points, according to the LDH release data
set. The time points in each cell system at which synergy was observed (Table 5) are
shown in red.
Concentration of max svnergy (tM)
Drug Rat hepatocvtes HepG2s
12hr 24hr 48hr 12hr 24hr 48hr
Buspirone 94 63 110 175 175
Nefazodone 110 79 79 125 75
Clarithromycin 429 286 286 364 243 61
Telithromvcin 357 357 357 121 121 121
Aspirin 857 857 1000 750 643
Nimesulide 1000 857 857 750 429 214
Ranitidine 571 1000 857 571 857 857
Cimetidine 429 - 1000 - - 857
Levofloxacin 343 - 114 686 343 229
Trovafloxacin 343 686 686 457 343 114
Entacapone 714 571 429 514 600 -
Tolcapone 429 143 143 - 86 -
[
Table 5. Drugs selected for testing in the 5-cytokine/LPS multiplex experiment. The
concentration used in subsequent experiments is shown for a given drug, as well as the
cell system and time point in which synergy was previously observed.
Drugs selection for drug-cytokine combinatorial experiments
Drug
Nefazodone
Clarithromycin
Telithromycin
Nimesulide
Ranitidine
Trovafloxaci n
Concentration
(^M, vs Cmax)
75 tM = 78*Cmax
175 pM = 52*Cmax
175 pM = 63*Cmax
450 pM = 21*Cmax
450 pM = 317*Cmax
450 pM = 59*Cmax
End point
Synergy with Synergy in
cytokine mix in... LPS-administered
HepG2 animal model
Rat hep's cells (Roth group)
24 hr
24, 48 hr
24, 48 hr
24 hr
not reported
not reported
not reported
not reported
+
24, 48 hr
24 hr
Color key: Compound not associated with liver injury
Compound associated with idiosyncratic liver injury (DILl P2)
5 5-cytokine/LPS multiplexing
5.1 Results from human hepatoma cell line
The most prominent trend evident from both the caspase 3/7 activity and LDH release
assays was the overwhelmingly synergistic effect of TNF across multiple drug
backgrounds (Figure 17). Even by inspection, TNF was clearly shown to play a role in
determining hepatotoxicity in the HepG2 cell line (Figures A3, A5). This was especially
true in the cases of clarithromycin, nefazodone, trovafloxacin, and nimesulide.
Interestingly, TNF was calculated to have a significant main effect on caspase 3/7 activity
assay values across all backgrounds at both time points (Figure A4). These effects
dominated other effects and interactions in the cases of all four drug backgrounds
previously mentioned. In the cases of DMSO and ranitidine backgrounds at both 24 and
48 hours, IFNy was also calculated to have a significant effect. However, as explained in
Section 2.3.1, these single effects cannot be interpreted because of their inclusion in the
significant two-factor interaction TNF x IFNy. This two-factor interaction was also
significant in the presence of clarithromycin, as was the negative interaction between
TNF and IL- la. This significant negative TNF x IL-1 a interaction was seen in the
presence of nefazodone and trovafloxacin as well. Over a background of nefazodone,
IFNy showed a significant main effect at 24 hours in the HepG2s, as did IL-la.
Factorial effects calculated from the LDH release assay also identified TNF as having
the most prominent effect among the cytokine/LPS combinations across the data set,
again especially in the cases of clarithromycin, nefazodone, trovafloxacin, and
nimesulide (Figure A6). This assay measured some of the same factorial trends that were
mentioned earlier from the caspase 3/7 activity assay data, but they were not significant.
As would be expected, measured toxicities were generally greater at 48 than 24 hours
(Figures A3, A5). Also, the relatively high toxicity levels measured by caspase 3/7
activity in the presence of TNF and IFNy over a background of clarithromycin were not
picked up by the LDH release assay (Figure 17).
5.2 Results from primary rat hepatocytes
Similar to the HepG2s, many of the TNF main effects were calculated to be
statistically significant from caspase 3/7 activity data (Figure A8). In fact, the drug
backgrounds for which the effect of TNF was statistically significant are the same that
were prominent by the same assay at the same time point in the human hepatoma data set
(Figures A4, A8), although by inspection only clarithromycin and trovafloxacin data sets
exhibited this trend at 24 hours (Figure A7). A statistically significant two-factor
interaction between IL-l a and 11-6 was measured over a DMSO background by the
caspase 3/7 activity assay at 24 hours (Figure A8), as well as by both assays at 48 hours
(Figures A8, A10). As before, this means that the significant effect of IL-la at 48 hours
as measured by the LDH release assay cannot be individually interpreted (Figure A 10).
Additionally, a consistent TNF x IL-la interaction was clear at both time points in the
primary rat hepatocytes in the presence of clarithromycin (Figures A8, A10). Those LDH
release assay values measured at 24 hours were also overwhelmed by the high toxicity
values that were measured in the presence of nimesulide across the range of treatment
conditions; the fold change scale measured for this data set was two to three times that
measured for any of the other assay value heat maps presented in Figure 17. However,
this data is consistent with that from the primary rat hepatocytes in Figure 12. In the same
way, the corresponding heat map of factorial effects calculated from LDH release assay
data at 24 hours (Figure 17) was overwhelmed by the prominent main effect of TNF that
was measured in the presence of trovafloxacin (Figure A10).
5.3 General trends across the data set
It must be noted that LPS was calculated to have significant effects in only three
backgrounds across this data set and that none of them were very prominent (Figures A4,
A8, A10). In addition, the prominent TNF x IL-la interaction noted in HepG2s was also
present in the primary rat hepatocytes. TNF and IFNy seemed to independently have
significant effects on toxicity in both cell systems, as measured by both assays at 24 and
48 hours (Figure 17). Toxicity increased noticeably across the range of treatment
conditions by 48 hours as well.
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5.4 Further analysis
The HepG2 data from 24 hours as measured by the caspase 3/7 activity assay was
subsequently analyzed using a joint entropy estimation to identify those subsets of
particularly informative cytokine treatments (Figure 18). Subsets of cytokine treatments
were evaluated with as few as four and as many as 32 cytokine treatment conditions.
Many unique cytokine treatments that were among the most representative subset of five
treatments were also among the most representative subset of 15 treatments (e.g.
TNF+LPS and TNF+IL-6+LPS). The cytokine combination of TNF and IL-6 most
commonly appeared as a member of the informative subset, and cytokine mix C was a
member of the most representative 4-treatment subset and the most representative 10-
treatment subset, as well as a member of more populated subsets (Figure 18). In Figure
19, the entropies of these subsets that were optimized to contain the maximum amount of
outcome information (best) are plotted versus the entropies of subsets that would have
been chosen at random among the estimated 1000 subsets (average). Note that maximum
joint entropy was reached by a 15-treatment set, indicating that more complicated
treatment sets do not contain any more net residual information about drug-cytokine
toxicity synergies. Also note that 90% of the total joint entropy was captured in the 10-
treatment set.
Euclidean clustering of the caspase 3/7 activity data set from the HepG2 cell line at
24 hours qualitatively confirmed many of general trends that were observed by inspection
(Figure 20). Data from the DMSO control, ranitidine, and telithromycin backgrounds
clustered together as the least cytotoxic data sets. This was expected of both drugs since
they previously displayed minimal drug-cytokine synergy in the human hepatoma cell
line (Table 5). As we have seen previously, increasing toxicity was generally associated
with higher-order cytokine combinations (Figure 20). In particular, the presence of TNF
in a given cytokine mix was the most significant determinant of treatment clustering,
followed by either IFNy or IL-la. The most informative cytokine treatment conditions
chosen in the 10-treatment joint entropy evaluation are distributed into many clusters
rather than into a few high toxicity clusters, illustrating the ability of joint entropy
analysis to identify a treatment subset that exhibits a diverse set of toxicity outcomes.
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Figure 18. Selection matrix to choose the most representative set of cytokine
treatments, given a specific number of possible cytokine conditions. The subset of the
highest calculated joint entropy was chosen. Entropies of selected treatment sets (bottom)
and accumulated for each treatment condition (right) are plotted in red [Bracken King].
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Figure 19. Comparison of the information content described by an average subset of
treatments versus the best (most informative) treatment set as identified in Figure
18, given a specific number of conditions [Bracken King].
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Figure 20. Euclidean clustering of the caspase 3/7 activity data set from the HepG2
human hepatoma cell line at 24 hours. TNF, followed by either IFNy or IL-I a, were
major determinants of treatment clustering. Those ten treatments that were identified by
the joint entropy-based evaluation to best predict the outcomes in this data set are noted.
5.5 Conclusions
It is interesting that TNF figured so prominently in the factorial effects calculated for
both the HepG2s and primary rat hepatocytes. As shown in Figure 21, its signal is
transduced upon receptor binding via the IB, JNK, and p38 MAPK pathways. It is
important, however, to keep in mind that the significant factorial contribution of TNF
does not imply that TNF is the most informative or representative of the cytokines in
predicting toxicity outcomes. In fact, TNF does not appear alone in the joint entropy-
based treatment selection matrix until a subset of 12 conditions is considered (Figure 18).
Moreover, the absence of cytokines appears in a subset before the first cytokine-alone
condition is included (IFNy), and no cytokine-only treatments are included in the Top 10.
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Rather, this factorial data should be interpreted to mean that the presence of TNF in a
given treatment mix generally increases its toxicity, and this increase is sometimes
irrespective of the presence or absence of other cytokines/LPS. Also, it may be inferred
that significant negative two-order interactions, in which the two cytokines/LPS also have
significant positive main effects, result from signaling pathways being overwhelmed in
the presence of both cytokines/LPS.
Variations across the data set as measured by caspase 3/7 activity and LDH release
assays may result from differences in the mechanism of cell death, in the cell systems
themselves, or both. For example, the toxicity measured in HepG2s in the presence of
TNF and IFN7 over a clarithromycin background by caspase 3/7 activity was relatively
greater than that measured by the LDH release assay (Figure 17). Potentially, this could
be explained by the presence of apoptotic cells, which had not yet undergone secondary
necrosis. Furthermore, it is encouraging that the results compiled in Table 5 are repeated
in Figure 17; nimesulide and ranitidine only showed synergistic toxicity in the HepG2
cell line and primary rat hepatocytes, respectively.
6 Discussion
Having established a systematic multiplexing approach, we developed an in vitro
system to study and model cytokine-mediated idiosyncratic drug hepatotoxicity,
recapitulating the in vivo situation. It is promising that some of the treatment-outcomes
we observed clearly demonstrated the same phenotypes as those seen by Roth's group. In
our model, unique inflammatory cytokine stimulation caused cell system-specific
hepatotoxicity, which may be extended in the future to include animal model- or patient-
specific toxicity as well. We consistently saw synergistic toxicity in the presence of
multiple idiosyncratic drugs across a landscape of inflammatory backgrounds. It would
be interesting to obtain data showing animal-to-animal or patient-to-patient variability in
cytokine upregulation following LPS administration or other inflammatory stimulation to
support our hypothesis that unique cytokine backgrounds mediate drug toxicity
outcomes. In fairness, however, it must also be mentioned that many of the cases of
idiosyncratic drug hepatotoxicity in vivo occurred in patients with chronic - versus acute -
inflammation, a condition that has not been extensively examined in our in vitro systems.
Additionally, some of the drugs we tested might interfere with one or more of our lethal
endpoint assays due to enzyme inhibition; in particular, we hypothesize that this may be
the case for telithromycin and trovafloxacin. In the future, we intend to investigate and
potentially correct for these interactions, while following up on this study by testing for
synergistic toxicity between the Top 10 cytokine/LPS combinations and multiple drugs in
primary hepatocytes and by further querying mechanisms of hepatotoxicity via cell
imaging and intracellular signaling platforms. This model may one day be used to
identify diagnostic biomarkers that predict the effects of treatments and interventions for
therapeutic applications.
7 Future Work
7.1 Primary human hepatocytes
We hope to compare our data from HepG2s and primary rat hepatocytes to that from
cryo-preserved primary human cellular systems (CellzDirect) to investigate the
similarities and differences in their responses to drug administration, given an induced
inflammatory environment. The ten or so cytokine/LPS combinations identified to be the
most informative by joint entropy calculations and shown to exhibit a range of toxicities
will be co-administered with drugs to effectively cover a landscape of phenotypic
responses and cell signaling pathways.
7.2 Cellomics imaging
In the future we also hope to measure the responses of various cell systems using the
Cellomics platform at Pfizer's Research Technology Center in Cambridge, MA. This
high-throughput imager assesses nuclei, lipid, and glutathione content, as well as bile
canaliculi function, mitochondrial membrane potential, and reactive oxygen species, of
single cells. Measurements of these sub-lethal toxicities may provide more information
regarding the mechanisms of hepatotoxicity.
7.3 Intracellular signaling
A systems-level approach is necessary to quantify the complex signal transduction
between environmental cues and intracellular signals that define disease states, building a
landscape of "toxicity-associated" signaling and hopefully elucidating mechanisms of
hepatocarcinogenesis. The high-throughput, quantitative multiplex Bio-Plex technology
from Bio-Rad Laboratories in Hercules, CA, utilizes multiplex bead-based assays to
evaluate the phosphorylation states within particular pathways of signaling proteins.
Sampling phosphoprotein levels at critical nodes within this network will quantitatively
monitor information flow regarding hepatocyte injury. Identifying relevant kinases, such
as Akt (Ser473), ERKI/2 (Thr202/Tyr 04 , Thr185/Tyr187), GSK-3a/f3 (Ser21/Ser9), IKB-a
(Ser32/Ser36), JNK (Thr83/Tyr185), p3 8 MAPK (Thr180/Tyr1 82), STAT3 (Tyr705), HSP27
(Ser 78), IRS-1 (Ser636/Ser639), MEK1 (Ser2 17/Ser22 1), p53 (Ser1 5), Histone H3 (Serlo), and
p70 S6 kinase (Thr421/Ser424), in the idiosyncratic drug hepatotoxicity pathway and
monitoring their levels with respect to time will help construct quantitative, dynamic,
predictive models of cue-signal-phenotypic response relationships that include key nodes
in all the major pathways. In this model of cytokine-induced hepatotoxicity, idiosyncratic
and non-idiosyncratic drugs will be co-administered to susceptible cytokine/LPS-
stimulated hepatocytes, and kinase phosphorylation will be monitored with time to
provide insight into the state of the signaling network. For the purposes of the PLSR
statistical model, we plan to focus on the ten or so cytokine treatments that were
identified using joint entropy evaluations to collect an intracellular signaling time course
data set in the presence and absence of both idiosyncratic and non-idiosyncratic drugs.
Preliminary experiments have already been performed to ensure Bio-Plex operation in a
linear dynamic range. Cell lysis and antibody detection were performed per the
manufacturer's recommendations and were analyzed using Luminex technology and Bio-
Plex Manager software. We hope this research would, in conjunction with data on drug
metabolism and the mechanism of drug toxicity, provide information regarding the cell
decision process.
Hepatocyte Signaling Network
MEASUREMENTS
Bioplex
KINASE Plate reader
Figure 21. Intracellular signaling network of hepatocytes. All cues used in this study
are identified, as well as some of the kinases whose phosphoprotein levels will be
measured using the Bio-Plex platform in future work [adapted from Leonidas
Alexopoulos].
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9 Appendices
9.1 Appendix 1. Hepatocyte growth medium recipe
Table Al. Recipe for hepatocyte growth medium, as added to 500 mL DMEM.
Supplement Final Concentration
L-Proline 0.030 mg/mL
L-Ornithine 0. 100 mg/mL
Niacinamide 0.305 mg/ml
D-(+)-Glucose 2.250 mg/ml
D-(+)-Galactose 2.000 mg/ml
BSA 2.000 mg/ml
ZnCl2 54.4 ng/ml
ZnSO4-7H20 75.0 ng/ml
CuSO4-5H20 20.0 ng/ml
MnSO4 25.0 ng/ml
L-Glutamine 1.0 mM
Sodiumselenite 5.0 ng/ml
Trichostatin A 300 ng/ml
Insulin 5.0 ug/ml
Dexamethasone 0.1 uM
Gentamicin 0.10%
Transferrin 5.0 ug/ml
*DMEM has 1.0 mg/mL D-(+)-Glucose
9.2 Appendix 2. Primary rat hepatocyte data from 6-cytokine/LPS multiplex
Primary rat hepatocytes
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Figure Al. Mean caspase 3/7 activity assay values across the 64 treatment conditions
and the factorial effects of those interactions in primary rat hepatocytes at two time
points. Error bars in all graphs represent the standard error across three or more
biological replicates.
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9.3 Appendix 3. HepG2 data from 5-cytokine/LPS multiplex
HepG2 cells
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Figure A3. Mean caspase 3/7 activity assay values for HepG2s at two time points in
the presence of six drugs. Error bars represent the standard error across five or more
biological replicates.
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9.4 Appendix 4. Primary rat hepatocyte data from 5-cytokine/LPS multiplex
Primary rat hepatocytes
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Figure A7. Mean caspase 3/7 activity assay values for primary rat hepatocytes at
two time points in the presence of six drugs. Error bars represent the standard error
across five or more biological replicates.
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bars represent the standard error across five or more biological replicates, and * denotes
statistical significance.
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Figure A9. Mean LDH release assay values for primary rat hepatocytes at two time
points in the presence of six drugs Error bars represent the standard error across five or
more biological replicates.
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Figure A10. Mean factorial effects calculated from LDH release assay values for
primary rat hepatocytes at two time points in the presence of six drugs. Error bars
represent the standard error across five or more biological replicates, and * denotes
statistical significance.
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